Clinical Trial

Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia

Name: Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia — clinical trial record (NCT07315373)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The goal of this clinical trial is to find the best dose of zanubrutinib when used together with high-dose dexamethasone for adults who are newly diagnosed with primary immune thrombocytopenia (ITP), and to learn how safe and effective this combination treatment is.

Trial Details

NCT Number	NCT07315373
Lead Sponsor	Peking University People's Hospital
Conditions	Immune Thrombocytopenia
Enrollment	60 participants
Start Date	2025-12-25
Primary Completion	2028-12-30 (estimated)
Study Completion	2029-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-01-02